Education Academy Logo
Journal Logo

Conference Abstracts - 2026 National Summit on Hematologic Cancers

Vol. 6, Issue Supplement 2, 2026 · S1-2

A Novel CD94-targeting CAR T Cell Therapy for Cytotoxic Subtypes of T/NK-cell Malignancies

Cao Cuong Le, PhD,Jinsheng Weng, PhD,Jingwei Liu, MD,Federico Mario Aletti, MD,Xiaoyun Cheng, MSc,Yongfu Tang, PhD,Sridevi Patchva, MBBS,Matthew D. Richard, BA,Mario L. Marques-Piubelli, BA,Luisa Solis, MD,Wei Le, PhD,Chun-Yen Lin, PhD,Fuliang Chu, PhD,Jingjing Cao, BA,Abdur Rehman, PhD,Lubna Rehman, PhD,Kamini Singh, PhD,Owhofasa Agbedia, MD,Sushanth Gouni, MD,Faezeh Darbaniyan, PhD,Balakrishnan Kumudha, PhD,Neeraj Saini, MD,Christopher Flowers, MD,Swami Lyer, MD,Francisco Vega, MD,Sattva Neelapu, MD

NK/T malignanciesCD94CAR-TSafety switch

Submission received: 2026-08-16 / Accepted: 2026-08-25 / Published: 2026-09-25

CCBY-SA-4.0
Publication: IJCCDhttps://doi.org/10.53876/001a.129849
3

Abstract

Background

Targeting pan-T-cell antigens with chimeric antigen receptor (CAR) T-cell therapy for T-cell lymphomas (TCL) may cause T-cell aplasia, which could predispose to severe infections. To address this, we developed a CAR-T product to target a post-thymic cell-of-origin antigen in T/NK-cell malignancies. Specifically, we describe a CAR-T product against CD94, a C-type lectin receptor expressed on subsets of normal NK (40-70%), (40-60%), and CD8 T cells (<10%), with the goal of targeting T/NK-cell neoplasms arising from these cytotoxic immune cells.

Methods

CD94 expression was evaluated by immunohistochemistry, flow cytometry, and single-cell RNAseq data in normal and/or tumor tissues. A second-generation CD94-targeting CAR incorporating a 4-1BB co-stimulatory domain and a truncated BCMA (tBCMA) safety switch was evaluated for safety and efficacy in in vitro and in vivo models.

Results

Among 33 normal tissues, CD94 expression was restricted to rare lymphocytes in secondary lymphoid organs and absent from other cell types. Among 46 T/NK-cell lymphomas, CD94 was highly expressed in NK/TCL (N=15/15), hepatosplenic TCL (N=7/7), and other cytotoxic T/NK-cell malignancies. CD94 CAR-T selectively eliminated CD94-positive but not CD94-negative isogenic NK-leukemia cell lines (p<0.0001). Complete tumor eradication occurred in two NK-leukemia cell line xenografts and patient-derived xenografts of hepatosplenic TCL and NK/TCL (p<0.01 for tumor burden and/or survival), including at doses as low as 2×10⁵ CAR-T cells/mouse using a 3-day manufactured CAR-T product. In humanized mice, CD94 CAR-T depleted CD94-positive NK and T-cell subsets while sparing CD94-negative counterparts and did not induce pan-T-cell aplasia. The tBCMA safety switch enabled rapid and sustained CAR-T elimination in mice after a one-time administration of teclistamab or belantamab mafodotin.

Conclusion

CD94 CAR-T demonstrated potent antitumor activity, did not induce pan-T-cell aplasia, and could be eliminated through the tBCMA safety switch. These findings supported launch of a Phase I clinical trial in CD94-positive T/NK-cell malignancies (NCT07382817).